On April 9, 2020 Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) reported the details of its cervical cancer awareness activities to increase the screening rate (Press release, Chugai, APR 9, 2020, View Source [SID1234556223]). The activities target the age group most at risk for developing cervical cancer and parents of adolescents.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The number of younger patients with cervical cancer has been increasing in recent years, particularly among those in their 20s to 40s.1) The cervical cancer screening is the only cancer screening program that is currently recommended by the Ministry of Health, Labour and Welfare (MHLW) for women aged 20 or above since this type of cancer should be detected at early curable stage.2) In Japan, however, the cervical cancer screening rate still remains at 42.1%,3) the lowest level in 30 member countries of the Organisation for Economic Co-operation and Development (OECD).

In order to eradicate cervical cancer, Chugai started disease awareness activities last year to improve the screening rate in Japan in collaboration with Osaka, Yokohama and other local governments. This year, Chugai rolls out further activities in partnership with Roche Diagnostics K.K. (Head Office, Tokyo; President and CEO, Makoto Ogasawara; hereinafter "RDKK"), the Japanese subsidiary of the Diagnostics Division of Roche Group, by leveraging the strengths of both companies. Specifically, the activities will include the shared use of disease awareness videos, brochures, and posters, as well as disease awareness initiatives through a tie-up with local governments with which we have concluded the comprehensive partnership agreements. RDKK has been actively focusing on the importance of early detection of cervical cancer with HPV testing and engaging in various awareness activities to prevent cervical cancer since 2009.

Main Activities
(1) Call for the importance of cervical cancer screening through commonly used media among young generation (e.g., Facebook, YouTube, and News app.).

Distribute educational articles to encourage the screening via Facebook(Chugai’s Official Facebook) and News App. (grape) at the occasion of Uterus Day (April 9).
Further provide young people with an opportunity to consider their health through Chugai’s educational video ("You…the one most responsible for you"; play time, 6 min. and 30 sec.) released last year on YouTube (View Source).
(2) Roll out activities in collaboration with local governments with which Chugai concluded the comprehensive partnership agreements and RDKK to increase the screening rate.

Conduct collaborative activities with RDKK by mutually utilizing each party’s expertise and materials to increase the screening rate particularly among women in their 20s with low screening rate, involving each local government.
Use an educational flyer for cervical cancer screening with Q&A to relieve uneasiness, clearly explaining the flow of the screening with illustrations. Distribute the flyer at coming-of-age ceremonies and universities in collaboration with each local government.
(3) Awareness activities to increase the screening rate among Chugai Group employees

Achieved improvement in the screening rate in some Chugai offices by establishing a system that allows employees to simultaneously undergo regular checkup and gynecological cancer screening in corporation with the health insurance association (the overall screening rate of cervical cancer screening which had been 60.4% in the previous year, increased to 62.9% across the company in 2019).
Conducted an in-house workshop presenting the current situation around cervical cancer in Japan at the occasion of World Cancer Day.
As a leading company in the oncology area, Chugai will continue to engage in disease awareness activities in oncology including gynecological cancer, which will lead to trust and appreciation from all stakeholders including patients, their families, and healthcare professionals.

On April 9, 2020 -X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, reported that management will present and conduct one-on-one meetings during the virtual 19th Annual Needham Healthcare Conference on Wednesday, April 15th, 2020 at 8:40 am EDT (Press release, X4 Pharmaceuticals, APR 9, 2020, View Source [SID1234556238]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the investor section of the X4 Pharmaceuticals website at www.x4pharma.com. After the live webcasts, the events will remain archived on the X4 Pharmaceuticals’ website for 90 days.

On April 9, 2020 West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, reported that it will release first-quarter 2020 financial results before the market opens on Thursday, April 23, 2020, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time (Press release, West Pharmaceutical Services, APR 9, 2020, View Source [SID1234556224]). To participate on the call, please dial 877-930-8295 (U.S.) or 253-336-8738 (International). The conference ID is 1865786.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live broadcast of the conference call will be available at the Company’s website, www.westpharma.com, in the "Investors" section. Management will refer to a slide presentation during the call, which will be made available on the day of the call. To view the presentation, select "Presentations" in the "Investors" section of the Company’s website.

An online archive of the broadcast will be available at the site three hours after the live call and will be available through Thursday, April 30, 2020, by dialing 855-859-2056 (U.S.) or 404-537-3406 (International). The conference ID is 1865786.

On April 9, 2020 RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy (BgRT)* to treat all stages of cancer, reported the first sale of its RefleXion X1 machine to the Stanford Cancer Institute (Press release, RefleXion Medical, APR 9, 2020, View Source [SID1234556239]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

RefleXion Co-Founder and Chief Technology Officer, Sam Mazin, Ph.D., first thought of using positron emission tomography (PET), widely considered the gold standard for diagnosing cancer, to instead treat tumors while attending a radiation physics lecture during his postdoctoral tenure. As the professor explained the difficulty in seeing tumors during cancer treatment, an idea began to form that he would pursue in earnest a few years later.

"The idea was to use individual emissions that make up a partially formed PET image, and are generated by the tumor, as a homing signal or biological marker to quickly guide radiotherapy to that location," explained Mazin. "In essence, turning cancer on itself to destroy it. It has been a rewarding journey from thinking of the idea years ago to co-founding RefleXion, and it is an honor to have Stanford as our first clinical and commercial client."

Mazin’s thought was to use PET in an entirely new way to solve one of the greatest challenges in radiotherapy: treating multiple tumors in the same session, even those in motion, so that radiotherapy could be offered to stage 4 cancer patients, for the first time, as a new treatment choice. RefleXion’s BgRT technology could one day expand radiotherapy from a treatment reserved for early-stage cancer, to an option for patients with multiple solid tumors throughout the body.

A novel modality under development, BgRT uses the biological signature of each tumor to characterize its movement and to track tumors more precisely for radiotherapy delivery. The RefleXion X1 machine with BgRT aims to overcome the technical limitations that currently restrict radiotherapy to one or two tumors. Once developed, RefleXion will scale BgRT to treat all visible tumors, even those that move rapidly due to bodily functions such as breathing or digestion, in the same treatment session.

Last month, RefleXion announced marketing clearance on the X1 machine for image-guided radiotherapy (also known as SBRT, SRS and IMRT), the first steppingstone on the path to BgRT. Installation of the X1 machine at the Stanford Medicine Cancer Center and patient treatments are scheduled to begin over the next few months.

On April 9, 2020 Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, reported that Chief Executive Officer, President and Chairman Kevin Hrusovsky will present at the 19th Annual Needham Healthcare Conference, on April 14, at 11:20 a.m., EDT (Press release, Quanterix, APR 9, 2020, View Source [SID1234556240]). The live webcast will be available in the Investor section of the Quanterix website at View Source Replays of the webcast will be available on the Quanterix website for 90 days following the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!